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Non-typeable Haemophilus influenza (NTHi) is an important human pathogen causing respiratory tract infections in both
adults and children. NTHi infections are characterized by inflammation, which is mainly mediated by nuclear transcription
factor kappaB (NF-kB)-dependent production of inflammatory mediators. The deubiquitinating enzyme cylindromatosis
(CYLD), loss of which was originally reported to cause a benign human syndrome called cylindromatosis, has been identified as
a key negative regulator for NF-kB in vitro. However, little is known about the role of CYLD in bacteria-induced inflammation in
vivo. Here, we provided direct evidence for the negative role of CYLD in NTHi-induced inflammation of the mice in vivo. Our
data demonstrated that CYLD is induced by NTHi in the middle ear and lung of mice. NTHi-induced CYLD, in turn, negatively
regulates NTHi-induced NF-kB activation through deubiquitinating TRAF6 and 7 and down-regulates inflammation. Our data
thus indicate that CYLD acts as a negative regulator for NF-kB-dependent inflammation in vivo, hence protecting the host
against detrimental inflammatory response to NTHi infection.
Citation: Lim JH, Jono H, Koga T, Woo C-H, Ishinaga H, et al (2007) Tumor Suppressor CYLD Acts as a Negative Regulator for Non-Typeable
Haemophilus influenza-Induced Inflammation in the Middle Ear and Lung of Mice. PLoS ONE 2(10): e1032. doi:10.1371/journal.pone.0001032
INTRODUCTION
Nontypeable Haemophilus influenzae (NTHi), a gram-negative
bacterium, is an important human pathogen in both adults and
children [1]. In adults, it exacerbates chronic obstructive
pulmonary diseases, and in children, it causes otitis media, the
most common childhood infection and the leading cause of
conductive hearing loss [2–4]. Despite the need for prophylactic
measures, development of a vaccine for preventing NTHi
infections has been difficult and still remains a great challenge.
Moreover, inappropriate antibiotic treatment contributes to the
worldwide emergence of antibiotic-resistant strains of NTHi.
Therefore, there is an urgent need for developing alternative
therapeutic strategies for the treatment of NTHi infections based
on understanding the molecular pathogenesis of NTHi infections.
Like most other bacterial infections, NTHi infection is character-
ized by inflammation, which is mainly mediated by nuclear factor
kappaB (NF-kB)-dependent production of pro-inflammatory
mediators [5–8]. We have previously shown that NTHi induces
Toll-like receptor (TLR) 2-dependent activation of NF-kB via an
IKKb-IkBa- and p38 mitogen-activated protein kinase (MAPK)-
dependent signaling pathway [6,9,10]. However, the key signaling
adaptors that link TLR2 with IKK and MAPK in mediating
NTHi-induced inflammation remain unknown.
Although the inflammatory response triggered by bacteria is
essential for eradicating bacterial pathogen, excessive inflamma-
tory response is clearly detrimental to the host, due to severe tissue
damage [11,12]. To avoid overactive and detrimental inflamma-
tory response in infectious disease, the bacteria-induced in-
flammatory response must be tightly regulated. During evolution,
the host has developed a variety of strategies to prevent
detrimental inflammatory response during bacterial infections.
Among all strategies, bacteria-induced negative feedback regula-
tion is thought to play a critical role in preventing overactive
inflammatory response by tightly regulating the activity of the key
receptor-dependent signaling adaptors specifically activated by
bacterial pathogens. In the pathogenesis of chronic obstructive
pulmonary diseases and otitis media, to avoid detrimental
inflammatory responses in NTHi infection, TLR2 signaling must
be tightly regulated. However, despite the importance of tight
regulation in preventing overactive inflammatory response, the
molecular mechanisms underlying the negative feedback regula-
tion of inflammation in the pathogenesis of NTHi infection remain
unknown.
CYLD was originally identified as a tumor suppressor, loss of
which causes a benign human syndrome called cylindromatosis
[13–15]. In vitro studies have indicated that CYLD is a member of
the deubiquitinating enzyme family that specifically digests
polyubiquitin chains. Transfection studies showed that CYLD
deubiquitinates TRAF2 and TRAF6 and acts as a negative
regulator for activation of NF-kB by tumor necrosis factor
receptor (TNFR) and TLR [16–18]. Recently, we, together with
others, showed that CYLD also negatively regulates activation of
MAPKs, including p38 MAPK [19–22]. Moreover, the expression
of CYLD is itself under the control of NF-kB [20,23], suggesting
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activation and NF-kB-dependent gene expression. Given the
important role that NF-kB plays in host immune and inflamma-
tory response in bacteria infection, it is logical to hypothesize that
CYLD may act as a negative regulator for immune and
inflammatory response against invading bacteria such as NTHi
in vivo. However, despite recent studies demonstrating the role of
CYLD in regulating T cell receptor signaling and tumor cell
proliferation in vivo, the biological role of CYLD especially its
negative role in inflammation in vivo still remains unknown.
In the present study, by using NTHi-induced otitis media and
pneumonia model in wild type (WT) and Cyld-deficient mice, we
provide in vivo evidence that NTHi induces pro-inflammatory
response through TLR2-dependent MyD88-TRAF6/7-NF-kB
signaling pathway, and CYLD negatively regulates NF-kB-
dependent inflammatory response by NTHi via deubiquitination
of TRAF6 and TRAF7. These studies may lead to development of
novel therapeutic strategies for controlling overactive inflamma-
tory response in respiratory bacterial infections.
MATERIALS AND METHODS
Mice
Cyld
2/2 mice were generated by homologous recombination as
previously reported [21]. A Cyld-gene targeting construct was
designed to delete exons 2 and 3 and replace them with a lacZ
reporter and a neomycin resistance gene. The targeting vector was
linearized and electroporated into 129S ES cells. Clones resistant
to G417 were selected and screened for homologous recombinants
by Southern blot analysis. Two targeted ES cell clones were
microinjected into C57BL/6 blastocysts, and the resulting
chimeras were mated to C57BL/6 females to generate mice
heterozygous for the Cyld mutation. Homozygous knockout
animals were obtained by mating of heterozygous males and
females. Genotyping was performed by PCR on tail-derived
genomic DNA, and absence of RNA transcript and protein
expression was confirmed by RT-PCR and Western blot analysis.
Tlr2
2/2 and MyD88
+/2 were described previously [24].
Animal experiments
For NTHi-induced otitis media model in WT and Cyld
2/2 mice,
anaesthetized mice were transtympanically inoculated with 1610
7
CFU of NTHi under the surgical microscope, and saline was
inoculated as control. The inoculated mice were then sacrificed by
intraperitoneal inoculation of 100 mg/kg sodium pentobarbital at
3, 6, 9, 24, 72, and 168 hours after inoculation of NTHi. Eardrum
was inspected under the otoscope and findings were recorded. To
assess the mRNA expression of inflammatory mediators, total
RNA was extracted from the bulla of NTHi and saline-inoculated
ear at the time points indicated above and real-time quantitative
PCR (Q-PCR) was performed as described previously [20]. For
histological analysis, dissected temporal bones were fixed with
10% buffered formaldehyde overnight with rocking, decalcified
with CalEX, embedded in paraffin, and sectioned at 5-mM
thickness. Sections were then stained with hematoxylin and eosin
(H&E) to visualize inflammatory response and pathological
changes in the middle ear. H&E-stained middle ear sections were
then evaluated by light microscopy using Axiovert 40 CFL (Carl
Zeiss), and images were recorded with an AxioCam MRC (Carl
Zeiss). NTHi culture positivity was confirmed by bacterial culture
of middle ear effusion from NTHi-inoculated ears.
For NTHi-induced pneumonia model in WT and Cyld
2/2,
Tlr2
2/2, and MyD88
+/2 mice, anaesthetized mice were intra-
tracheally inoculated with 5610
7 CFU of NTHi, and saline was
inoculated as control. The inoculated mice were then sacrificed by
intraperitoneal inoculation of 100 mg/kg sodium pentobarbital at
the time points indicated above. For histological analysis, dissected
lung was inflated and fixed with 10% buffered formaldehyde,
embedded in paraffin, and sectioned at 5-mM thickness. Sections
were then stained and inspected as described above. For
polymorphonuclear neutrophil (PMN) analysis, bronchoalveolar
lavage (BAL) was performed by cannulating the trachea with
sterilized PBS. Cells from BAL fluid were stained with Hemacolor
(EM Science) after cytocentrifugation (Thermo Electronic Co.). To
assess the mRNA expression of inflammatory mediators, total
RNA was extracted from the lung of NTHi and saline-inoculated
lung at the time points indicated above and Q-PCR was
performed as described previously [20]. All animal experiments
were approved by the Institutional Animal Care and Use
Committee at University of Rochester.
Bacteria strain and culture
Clinical isolate of NTHi wild-type strain 12 was used in in vitro cell
culture experiments and in vivo animal experiments [9]. Bacteria was
grown on chocolate agar at 37uC in an atmosphere of 5% CO2 for
overnightandinoculated inbrainheart infusion broth supplemented
with 3.5 mg of NAD per ml (BHI). After overnight incubation,
bacteria were subcultured into 5 ml of fresh BHI and the log phase
NTHi that was monitored by measurement of optical density (OD)
value was washed and suspended in phosphate-buffered saline for in
vitro cell experiments and in isotonic saline for in vivo animal
experiments. For in vitro experiments, the epithelial cells were treated
with NTHi at a multiplicity of infection (MOI) of 1:25 for various
times as indicated. For in vivo animal experiments, NTHi was
inoculatedintothemiddleearforotitismediamodeland thelungfor
pneumonia at a concentrationof1610
7 CFU/earand5610
7 CFU/
lung, respectively.
Cell culture
Human middle ear epithelial cell line HMEEC-1, a commonly
used middle ear cell line, was derived by human papilloma
virus immortalization of primary human middle ear epithelial
cells, and was maintained in a 1:1 mixutre of Bronchial
Epithelial Basal Medium (BEBM) and Dulbecco’s modified
Eagle’s medium (DMEM) as described [6,9,25]. Airway
epithelial cell line A549 was maintained as described [9,26].
Primary normal human bronchial epithelial cell (NHBE) were
purchased from Cambrex and were maintained as described
previously in Bronchial Epithelial cell Growth Medium (BEGM)
[6,23,25]. For air-liquid interface culture, NHBE cells were
cultured as described previously [27]. In brief, NHBE cells were
seeded at 2610
4 cells/cm
2 onto 24-mm-diameter, 0.4 mm pore
size, semi-permeable membrane inserts (Corning) in BEBM.
The cultures were grown submerged for the first 7 days and
then, the air-liquid interface was created by removing media
from the apical compartment of the cultures. The culture media
were changed every other day until the air-liquid interface was
created and were changed daily by replacing fresh media only
to the basal compartment during the air-liquid interface culture.
NHBE cells were grown in air-liquid interface for 2–3 weeks
before being used for the proposed experiments. All cells were
cultured in a humidified atmosphere of 5% CO2 and 95% air
at 37uC.
Transfection and Small Interfering RNA (siRNA)
The plasmids TLR2, MyD88, TRAF6, and TRAF7 DN, WT
CYLD, and NF-kB-luciferase reporter were described previously
CYLD in In Vivo Inflammation
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24 hours, cells were co-transfected with or without NF-kB-
luciferase reporter plasmid and various expression plasmids as
indicated in the figure legends. Empty vector was used as a control
and was added where necessary to ensure a constant amount of
input DNA. All transient transfections were carried out in
triplicate using a TransIT-LT1 reagent (Mirus Co.) following the
manufacturer’s instructions. At 40 hours after the start of trans-
fection, cells were inoculated with NTHi for 5 hours before cell
lysis for luciferase assay or mRNA analysis as described previously.
RNA-mediated interference for down-regulating CYLD expres-
sion was done using siRNA-CYLD as described previously
[20,23].
Western blot (WB) analysis and
immunoprecipitation (IP)
Antibodies against TRAF6, HA and Ubiquitin were purchased
from Santa Cruz Biotechnology, and CYLD was from IMGE-
NEX.
Western blots were performed as described [20,23] and
following the manufacturer’s instruction. Briefly, Western blots
were performed using whole cell extracts, separated on 8–10%
SDS-PAGE gels, and transferred to poly-vinylidine difluoride
membranes. The membrane was blocked with 5% nonfat milk,
incubated in a 1:2,000 dilution of a primary antibody, and
incubated with 1:2,000 dilution of the corresponding secondary
Figure 1. Cyld
2/2 mice are hyperresponsive to NTHi-induced inflammation in the ear and lung of the mice. A, NTHi was trans-tympanically
inoculated into the middle ears of WT and Cyld
2/2 mice and bullaes were dissected from WT and Cyld
2/2 mice inoculated with NTHi and saline for
the control for histological analysis (H&E stain, 200X). B, NTHi was intratracheally inoculated into the lungs of WT and Cyld
2/2 mice and lung tissues
were dissected from WT and Cyld
2/2 mice inoculated with NTHi and saline for the control for histological analysis (H&E stain, 2006). C&D , NTHi was
trans-tympanically (C) or intratracheally (D) inoculated into the middle ear (C) or lung (D), respectively, of WT and Cyld
2/2 mice and mRNA expression
of the inflammatory mediators, IL-1b and MIP-2, was measured by Q-PCR analysis *p,0.005 compared with control inoculation in WT mice, **p,0.05
compared with NTHi inoculation in WT mice. Values are means 6 S.D. (n=3). CON, control.
doi:10.1371/journal.pone.0001032.g001
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reagent ECL to visualize to blots. For immunoprecipitation, cell
lysates were immunoprecipitated with 1 mg of the appropriate
antibodies for overnight at 4uC and then conjugated to protein A/
G-agarose beads for 2 hours at 4uC.
Statistical analysis
Data were analyzed using Student’s t-test. A value of p,0.05 was
considered significant.
RESULTS
Cyld
2/2 mice are hyperresponsive to NTHi-induced
inflammation in the ear and lung of the mice
To determine the biological role of CYLD in regulating
inflammation in vivo, Cyld-deficient mice were generated by using
standard targeting technique as described previously [21]. Briefly,
Cyld
2/2 mice were generated by replacing exons 2 and 3 of Cyld
gene with a neomycin resistance-lacZ cassette. Homozygous
mutant was ascertained by PCR genotyping from tail tissue of
mutant mice. RT-PCR analysis confirmed the absence of Cyld
transcripts in Cyld
2/2 mice, and immunoblot analysis of mouse
embryonic fibroblast (MEF) using an antibody against CYLD
showed Cyld deficiency. Cyld-deficient mice exhibit no overt
abnormalities and have a normal lifespan.
We next investigated the negative role of CYLD in in-
flammatory response against NTHi infection in the middle ear
and lung of Cyld
2/2 mice. Age- and sex-matched WT and
Cyld
2/2 mice were inoculated with NTHi and inflammatory
response in the middle ear and lung of infected mice was
monitored up to 7 days. Histological examination of the middle
ear revealed enhanced inflammatory responses including en-
hanced leukocyte infiltration in Cyld
2/2 mice compared with WT
mice (Fig. 1A). Consistent with this result, histological evaluation
of the lung of NTHi-inoculated mice showed enhanced leukocyte
infiltration in peribroncheal and interstitial area in Cyld
2/2 mice
compared with WT mice (Fig. 1B).
NTHi-induced inflammatory response and leukocyte infiltration
are mediated by pro-inflammatory mediators, including IL-1b and
MIP-2 [5,6]. Thus we measured expression of IL-1b and MIP-2 at
mRNA levels in the middle ear and lung from both WT and
Cyld
2/2 mice 9 hours after NTHi inoculation. Compared with
WT mice, Cyld
2/2 mice showed higher levels of IL-1b and MIP-2
mRNA expression in the middle ear (Fig. 1C) and in the lung
(Fig. 1D). In addition, we also found significant increases in the
levels of TNF-a mRNA expression in Cyld
2/2 mice (data not
Figure 2. NTHi-induced CYLD is responsible for down-regulation of inflammatory response. A & B, NTHi induced CYLD expression at both mRNA
(A) and protein levels (B) in HMEEC-1 cells. C, NTHi induced CYLD expression at the mRNA level in the middle ear of WT mice. D&E , NTHi induced
expression of CYLD and IL-1b (D) or MIP-2 (E) at the mRNA level in the lung of WT mice. *p,0.05 compared with CON. Values are means 6 S.D. (n=3).
CON, control.
doi:10.1371/journal.pone.0001032.g002
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role in negatively regulating NTHi-induced inflammatory re-
sponse in vivo.
NTHi-induced CYLD is responsible for
down-regulation of inflammatory response
It is well known that a variety of genes involved in inflammatory
response undergo changes in expression pattern in response to
bacterial infection [28–30]. We recently found that the endoge-
nous expression level of CYLD is relatively low in middle ear and
lung under physiological condition [13], but highly inducible by
bacterial pathogens [20,23], we hypothesized that CYLD is
induced by NTHi and increased CYLD expression will in turn
lead to inhibition of NTHi-induced inflammatory response,
thereby preventing overactive inflammatory response that is
detrimental to the host. We tested our hypothesis by first
evaluating the effect of NTHi on CYLD expression. As shown
in Fig. 2A, NTHi induced CYLD expression at the mRNA level
in middle ear HMEEC-1 cells. The induction of CYLD by NTHi
was also confirmed at the protein level by performing Western blot
analysis (Fig. 2B). Similar result was also observed in human
airway A549 cells and the primary human airway epithelial cells
cultured under both regular liquid culture and physiological air-
liquid interface condition (Data not shown). Moreover, up-
regulation of CYLD by NTHi was also observed in the middle
ear of NTHi-inoculated WT mice (Fig. 2C). Marked induction of
CYLD by NTHi was observed at 6–9 hours, and an even greater
induction of CYLD was still observed at 3–7 days. Consistent with
these findings, marked induction of CYLD by NTHi was observed
in the lungs of NTHi-inoculated WT mice along with down-
regulation of pro-inflammatory mediators, IL-1b and MIP-2
(Fig. 2D & E). It is interesting to note that the peak of CYLD
induction was clearly preceded by the peak of the induction of IL-
1b and MIP-2, thereby suggesting that NTHi-induced CYLD is
responsible for down-regulation of inflammatory response.
Figure 3. NTHi induces inflammatory response through TLR2-MyD88-TRAF6/7-NF-kB signaling pathway. A & B, Overexpressing dominant-
negative (DN) mutants of TLR2, MyD88 and TRAF6/7 inhibited NTHi-induced activation of NF-kB( A) and up-regulation of IL-1b and IL-8 (B) in HMEEC-
1 cells. *p,0.001, compared with Mock. Values are means 6 S.D. (n=3). C, NTHi-induced expressions of IL-1b and MIP-2 mRNA were reduced in the
lung of Tlr2
2/2 mice in vivo.* p,0.005, compared with CON in WT mice, **p,0.05 compared with NTHi inoculation in WT mice. Values are means 6
S.D. (n=3). D, NTHi-induced expressions of IL-1b and MIP-2 were reduced in the lung of MyD88
+/2 mice in vivo. E, Histological analysis of lung of
Tlr2
2/2 mice revealed reduced inflammatory response by NTHi compared with WT mice (H&E stain, 6200).
doi:10.1371/journal.pone.0001032.g003
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TLR2-MyD88-TRAF6/7-NF-kB signaling pathway
We next sought to identify the molecular target of CYLD in
negatively regulating NTHi-induced inflammation. We first
examined if TLR2-MyD88 and TRAFs, a family of adaptor
proteins, are critically involved in mediating NTHi-induced
inflammation. As shown in Fig. 3A, overexpressing dominant-
negative mutants of TLR2, MyD88 or TRAF6 or TRAF7, a newly
identified member of TRAF family, inhibited NF-kB activation by
NTHi in human middle ear HMEEC-1 cells. Similar results were
also observed in human airway epithelial A549 cells and human
primary bronchial epithelial NHBE cells (Data not shown).
Moreover, overexpressing dominant-negative mutants of
MyD88, TRAF6 or TRAF7 also inhibited NTHi-induced
expression of IL-1b and IL-8 in HMEEC-1 cells (Fig. 3B).
Consistent with these in vitro findings, Tlr2
2/2 mice showed
significant reduction in both IL-1b and MIP-2 expression, when
mice were intratracheally inoculated with NTHi (Fig. 3C).
Similar result was observed in MyD88
+/2 mice (Fig. 3D).
Moreover, histological analysis of lungs of NTHi-inoculated mice
revealed markedly reduced inflammatory response in Tlr2
2/2
mice compared with WT mice (Fig. 3E). Thus, it is evident that
TLR2-dependent MyD88-TRAF6/7 signaling pathway plays
a critical role in mediating NTHi-induced NF-kB-dependent
inflammatory response in vitro and in vivo.
CYLD acts as a negative regulator for NTHi-induced
NF-kB activation via negative cross-talk with
TRAF6/7
Having demonstrated the critical role of TLR2-dependent
MyD88-TRAF6/7 signaling pathway in NTHi-induced NF-kB-
dependent inflammatory response, we next sought to determine if
CYLD negatively regulates NTHi-induced NF-kB activation by
targeting TRAF6/7. We initially evaluated the role of CYLD in
activation of NF-kB and the resultant cytokine induction by NTHi
by CYLD knockdown in human middle ear epithelial HMEEC-1
cells. We first confirmed the efficiency of CYLD-specific siRNA
(siRNA-CYLD) in reducing CYLD expression. As expected,
endogenous CYLD protein was markedly reduced by siRNA
(Fig. 4A, upper panel). CYLD knockdown by using siRNA-
CYLD enhanced activation of NF-kB by NTHi, whereas
overexpression of WT-CYLD inhibited it (Fig. 4A, lower panel
& Fig. 4B). Moreover, CYLD knockdown enhanced NTHi-
induced DNA binding activity of NF-kB( Fig. 4C). Consistent
with these results, siRNA-CYLD also enhanced the induction of
Figure 4. CYLD acts as a negative regulator for NTHi-induced NF-kB activation via negative cross-talk with TRAF6/7. A. CYLD knockdown by
siRNA-CYLD markedly reduced expression of CYLD and enhanced NTHi-induced NF-kB-dependent promoter activity in HMEEC cells. B,
overexpression of WT-CYLD inhibited NTHi-induced NF-kB-dependent promoter activity in HMEEC cells. C, NTHi-induced DNA binding activity of NF-
kB was enhanced by CYLD knockdown, as assessed by EMSA. D, CYLD knockdown by siRNA-CYLD enhanced NTHi-induced IL-1b and IL-8 expression
at mRNA level in HMEEC-1 cells. E, TRAF7 synergistically enhanced TRAF6-induced NF-kB-dependent promoter activity. Overexpression of WT-CYLD
inhibited TRAF6- and TRAF7-induced NF-kB-dependent promoter activity, whereas CYLD knockdown by siRNA-CYLD enhanced TRAF6- and TRAF7-
induced NF-kB-dependent promoter activity in lung epithelial A549 cells. *p,0.05, compared with NTHi-inoculated in Mock in A, B and D. Values are
means 6 S.D. (n=3).
doi:10.1371/journal.pone.0001032.g004
CYLD in In Vivo Inflammation
PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e1032IL-1b and IL-8 expression by NTHi in middle ear epithelial
HMEEC-1 cells (Fig. 4D). Similar results were also observed in
human airway epithelial A549 cells and primary airway epithelial
NHBE cells (Data not shown). Our data thus suggest that CYLD
indeed acts as a negative regulator for NTHi-induced NF-kB-
dependent inflammatory response in middle ear and respiratory
epithelial cells.
We next sought to determine how CYLD inhibits NTHi-
induced NF-kB activation. We previously showed that TRAF7
cooperates with TRAF6 in mediating NF-kB activation. Since we
have shown that TRAF6 and 7 are involved in NTHi-induced
NF-kB activation, it is likely that CYLD may inhibit NTHi-
induced NF-kB activation by targeting TRAF6 and 7. We first
tested our hypothesis by evaluating if CYLD knockdown or
overexpressing WT CYLD alters NF-kB activation induced by
expressing WT TRAF6 and 7. As shown in Fig. 4E, TRAF7
synergistically enhanced TRAF6-induced NF-kB activation, and
overexpression of WT-CYLD inhibited TRAF6 and 7-induced
NF-kB activation, whereas CYLD knockdown by siRNA-CYLD
enhanced NF-kB activation induced by wt-TRAF6 and 7. Our
data thus suggests that CYLD inhibits NF-kB by targeting
TRAF6 and 7.
CYLD inhibits TRAF6 and TRAF7 in
a deubiquitination-dependent manner
Because CYLD is known as a deubiquitinating enzyme (DUB) and
polyubiquitination plays an important role in TRAFs activation
[16–18,20], we next determined if CYLD deubiquitinates TRAF6
and 7. We first examined whether NTHi induces polyubiquitina-
tion of TRAF6 and TRAF7. As shown in the Fig. 5A & C, NTHi
induced polyubiquitination of TRAF6 and TRAF7 in a time-
dependent manner, respectively. Moreover, co-expression of WT-
CYLD caused a reduction in TRAF6 and TRAF7 ubiquitination,
and CYLD knockdown by siRNA-CYLD markedly increased
levels of ubiquitinated TRAF6 and TRAF7 in HeLa cells (Fig. 5B
&D ). Together, we conclude that CYLD inhibits NTHi-induced
NF-kB-dependent inflammatory response by deubiquitinating
TRAF6 and TRAF7.
DISCUSSION
Negative feedback regulation plays a critical role in preventing
overactive and detrimental inflammatory response in a variety of
human diseases including infectious diseases [31]. To fully
understand the molecular mechanisms underlying the negative
Figure 5. CYLD inhibits TRAF6 and TRAF7 in a deubiquitination-dependent manner. A, NTHi induced ubiquitination of TRAF6. B, co-expressing
WT-CYLD inhibited, whereas CYLD knockdown by siRNA-CYLD enhanced the ubiquitination of TRAF6 in HeLa cells. C, NTHi induced ubiquitination of
TRAF7. D, co-expressing WT-CYLD inhibited, whereas CYLD knockdown by siRNA-CYLD enhanced the ubiquitination of TRAF7 in HeLa cells.
doi:10.1371/journal.pone.0001032.g005
CYLD in In Vivo Inflammation
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otitis media and chronic obstructive pulmonary diseases, it is
essential to identify the key receptor-mediated signaling adaptors.
We previously showed that TLR2 is required for NTHi-induced
NF-kB-dependent inflammatory response [6,9,10]. However, the
key signaling adaptors that link TLR2 with NF-kB still remain
unknown. In the present study, by overexpressing dominant-
negative mutants of TLR2, MyD88 and TRAF6/7 and by using
Tlr2
2/2 and MyD88
+/2 mice, we demonstrated that NTHi
induced NF-kB-dependent inflammatory response through TLR2-
dependent MyD88-TRAF6/7 signaling pathway (Fig. 6). This
finding is of particular interest because disrupting the signaling-
mediated by TRAFs, the bottleneck of the receptor-mediated
signaling, should efficiently block NTHi-induced TLR2-depen-
dent NF-kB activation and the subsequent inflammatory response.
Thus, the TRAF6/7 complex appears to be an attractive target for
therapeutic intervention [32–36]. Indeed, over the past decade
significant effort has been put into developing therapeutic
strategies to shut down TRAF6 signaling for reducing the
mortality associated with septic shock [37]. Since TRAF6/7
complex is essential for transducing NTHi-initiated signal from
surface TLR to the NF-kB in the nucleus, it would be thus an ideal
target for negative feedback regulation in the pathogenesis of
bacteria infection.
The deubiquitinating enzyme CYLD was initially identified as
a tumor suppressor because loss of which causes a benign human
tumor called cylindromatosis [13–15]. In vitro studies indicate that
CYLD inhibits TNF-a-induced NF-kB activation by deubiquiti-
nating TRAF2 [16–18]. Ubiquitination is previously known for its
role in targeting proteins for degradation by the proteasome, but
evidence of the nonproteolytic functions of ubiquitin is also rapidly
accumulating. Initial evidence for the regulatory, rather than
proteolytic, function of ubiquitin is provided by study of the TRAF
proteins, which function as ubiquitin ligases to synthesize lysine 63
(K63)-linked polyubiquitin chains to mediate activation of
downstream kinases through a proteasome-independent mecha-
Figure 6. Schematic representation of the negative regulation of NTHi-induced inflammatory response by CYLD.
doi:10.1371/journal.pone.0001032.g006
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deubiquitinating it, its role in deubiquitinating other TRAF family
members remains unclear. The role of CYLD in regulating NTHi-
induced NF-kB activation also remains unknown. Moreover,
despite its known role in regulating T-cell development and tumor
cell proliferation in vivo [39,40], its role in regulating inflammation
in bacterial infections in vivo is still unclear. In the present study, we
have shown that, by performing the inflammatory phenotype
analysis of Cyld
2/2 mice, CYLD negatively regulates NTHi-
induced inflammatory response in the middle ear and lung of
Cyld
2/2 mice (Fig. 1), and this negative regulation results in
enhanced pathological changes in the middle ear and lung as well
as increased expression of pro-inflammatory mediators in vivo.
Thus our data provide direct in vivo evidence for the negative
regulation of CYLD in NTHi-induced inflammation via a deubi-
quitination-dependent inhibition of TRAF6/7 in the middle ear
and lungs of mice.
In the present study, it is clear that CYLD acts as a critical
negative regulator for NTHi-induced inflammation in the middle
ear and lung. However, the expression of CYLD in the middle ear
and lung is relatively low under physiological condition. Moreover,
Cyld
2/2 mice exhibit no overt abnormalities under normal
conditions [21,40]. Moreover it was recently reported that
Cyld
2/2 mice are more susceptible to chemical-induced skin-
tumorigenesis even though they appear normal under physiolog-
ical condition. These interesting findings thus led us to hypothesize
that CYLD, although expressed at relatively low level under
physiological conditions, is up-regulated by bacteria during middle
ear and lung infection, which in turn leads to the attenuation of
NTHi-induced inflammation. In view of CYLD in negative
regulation of bacteria-induced TLR2-dependent inflammatory
response, it is interesting to note that CYLD expression itself is also
regulated by bacteria-induced TLR activation [20,23]. CYLD is
induced rapidly after activation of TLR2 by various bacterial
pathogens including PGN, MALP-2, Pam3CSK4, and NTHi.
Our finding reveals novel molecular mechanisms by which
bacterial pathogens including NTHi induce CYLD expression,
which in turn attenuates bacteria-induced inflammatory response.
Given that prolonged CYLD expression is anticipated to suppress
adequate host response to the invading pathogens, which is
necessary for the adequate host defense, it is also of particular
interest to investigate how CYLD expression is negatively
regulated. This study should provide novel insights into how
inflammation is tightly regulated and may lead to the development
of novel therapeutic strategies for modulating inflammation.
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